Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer
10:36pm, Monday, 08'th Aug 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, to
Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q2 2022 Results - Earnings Call Transcript
08:20am, Sunday, 07'th Aug 2022
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Holly Manning - Senior Director, Investor Relations Jackie Fouse - Chief Exec
Agios (AGIO) Q2 Loss Narrower Than Expected, Sales Beat
04:20pm, Friday, 05'th Aug 2022 Zacks Investment Research
Agios Pharmaceuticals' (AGIO) posts encouraging results for the second quarter. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.
Agios (AGIO) Q2 Loss Narrower Than Expected, Sales Beat
01:33pm, Friday, 05'th Aug 2022
Agios Pharmaceuticals' (AGIO) posts encouraging results for the second quarter. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
12:45pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.62% and 64.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Agios Reports Business Highlights and Second Quarter 2022 Financial Results
11:00am, Thursday, 04'th Aug 2022 GlobeNewswire Inc.
– Generated $3.1 Million in Net U.S. Revenue for First Full Quarter of PYRUKYND® (mitapivat) Sales –
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2022
02:03pm, Wednesday, 27'th Jul 2022 Benzinga
Upgrades
According to Edward Jones, the prior rating for NiSource Inc (NYSE:NI) was changed from Hold to Buy. For the first quarter, NiSource had an EPS of $0.75, compared to year-ago quarter EPS of
Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp
12:32am, Tuesday, 26'th Jul 2022
Agios sold its first successful commercial drug to Servier for $2 billion. Launch of second drug, Pyrukynd, is underway.
Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022
11:00am, Thursday, 14'th Jul 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, to
Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022
07:00am, Thursday, 14'th Jul 2022
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, toda
U.S. Stock Futures Higher; All Eyes On Inflation Data
10:03am, Wednesday, 13'th Jul 2022 Benzinga
Pre-open movers
U.S. stock futures traded higher in early pre-market trade on Wednesday after recording losses in the previous session. Investors are awaiting earnings results from Delta Air Lines, I
Delta Air Lines, Fastenal And 3 Stocks To Watch Heading Into Wednesday
07:38am, Wednesday, 13'th Jul 2022 Benzinga
With the US stock futures trading slightly higher this morning on Wednesday after recording losses in the previous session, some of the stocks that may grab investor focus today are as follows:
Wall
Agios Appoints Brian Goff as Chief Executive Officer
08:01pm, Tuesday, 12'th Jul 2022 GlobeNewswire Inc.
– Current CEO, Jackie Fouse, Ph.D., to Transition to Chair of Board of Directors Effective August 8, 2022 –
Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress
02:30pm, Friday, 10'th Jun 2022 GlobeNewswire Inc.
– Treatment with PYRUKYND® Associated with Early and Robust Hemoglobin Responses in Phase 3 ACTIVATE and Extension Studies; Approximately One-Third of Patients Achieved Normal Hemoglobin Levels at
7 Analysts Have This to Say About Agios Pharmaceuticals
01:12pm, Tuesday, 17'th May 2022 Benzinga
Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
1
2
0
1
